Milrineon (Milrinone Lactate Ampoules) 10mg/10ml

Milrineon (Milrinone Lactate) 10mg/10ml ampoules are prescribed for short-term management of severe heart failure. This phosphodiesterase inhibitor supports cardiac function in critical care settings. Ideal for emergency use, it requires professional administration. Store at ambient temperature.

Strength

10mg/10ml

Pack Size

Storage

Ambient

Manufacturer / TM Owner

Neon Laboratories LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Milrineon is used to treat severe heart failure when other medications are ineffective. It helps improve heart pumping ability in patients who need immediate cardiac support. Often used in hospital settings for acute decompensated heart failure. May also assist in post-cardiac surgery recovery where heart function is compromised.

Side Effects

Milrineon works by relaxing and widening blood vessels, reducing the heart's workload. It increases the heart's contractility, helping it pump more effectively. Patients may experience improved blood flow and oxygen delivery. Effects are typically observed shortly after administration.

Precautions & Warnings

Milrineon should only be handled and administered by trained healthcare professionals. Monitor heart rate, blood pressure, and electrolytes closely during use. Avoid use in patients with severe aortic or pulmonic valvular disease. Caution is advised in patients with kidney impairment due to potential accumulation.

Avoid Interactions

Milrineon may interact with other heart medications, including beta-blockers and diuretics. Combining with vasodilators can enhance blood pressure-lowering effects. Caution is needed when used alongside drugs that affect electrolyte balance. Always inform healthcare providers about all medications being taken.

Frequently Asked Questions

Milrineon is used for short-term treatment of severe heart failure when other therapies are not effective.

Milrineon is administered intravenously by healthcare professionals in a clinical setting.

Common effects may include headache, nausea, or changes in heart rhythm.

No, Milrineon requires professional administration and monitoring in a hospital or clinical environment.

Caution is advised in kidney impairment; doses may need adjustment based on kidney function.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.